Drug intelligence / Profile preview

ANG1009

Development stage
Preclinical
Lead developer
Angiochem
Modality
Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
Administration
Intravenous
01

Overview

ANG1009 is a preclinical peptide-drug conjugate (PDC) developed by Angiochem for the treatment of brain cancer. It utilizes Angiochem's proprietary EPiC (Engineered Peptide Compounds) platform, specifically the Angiopep-2 peptide, which is designed to cross the blood-brain barrier (BBB) by targeting the low-density lipoprotein receptor-related protein 1 (LRP1) via receptor-mediated transcytosis. The therapeutic payload is etoposide, a chemotherapy agent that inhibits DNA topoisomerase II, leading to double-stranded DNA breaks and cell death. By conjugating etoposide to the Angiopep-2 carrier, ANG1009 aims to overcome the poor CNS penetration of conventional etoposide, potentially providing a more effective treatment for primary brain tumors and brain metastases.

02

Targets

TOP2A (DNA topoisomerase II)LRP1 (Prolow-density lipoprotein receptor-related protein 1)

Beyond the preview

Go deeper on ANG1009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANG1009.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call